Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02275351 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
A Phase 2 study, sponsored by Biosplice Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 310
- Enrollment target
NCT02275351 is a Phase 2 study that has completed, run by Biosplice Therapeutics. The registered enrollment target is 310 participants.
The verdict
NCT02275351, a Phase 2 study, has completed, sponsored by Biosplice Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 310 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
Interventions
- DRUG Vehicle
- DRUG SM04554
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02275351
The ClinicalTrials.gov registry entry for NCT02275351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT02275351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02275351 about?
NCT02275351 is a clinical study titled "A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)". The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
What is the current status of trial NCT02275351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 310 participants. The study started on 2014-11. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02275351?
The interventions under investigation include: Vehicle (DRUG), SM04554 (DRUG).
Who is sponsoring clinical trial NCT02275351?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.